Profile data is unavailable for this security.
About the company
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
- Revenue in USD (TTM)0.00
- Net income in USD-23.06m
- Incorporated2015
- Employees14.00
- LocationCalciMedica Inc505 Coast Boulevard South, Suite 307LA JOLLA 92037United StatesUSA
- Phone+1 (858) 952-5500
- Fax+1 (302) 655-5049
- Websitehttps://calcimedica.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pulmatrix Inc | 0.00 | -5.16m | 6.90m | 2.00 | -- | 1.81 | -- | -- | -1.41 | -1.41 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -73.31 | -41.17 | -80.51 | -46.40 | -- | -- | -- | -257.55 | -- | -- | 0.00 | -- | -100.00 | -- | 46.00 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -2.34m | 6.99m | 6.00 | -- | 0.7152 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 7.07m | 37.00 | -- | 0.3128 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 7.09m | 22.00 | -- | 0.3039 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 7.14m | 2.00 | -- | 0.1343 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.58m | -11.29m | 7.15m | 16.00 | -- | 0.4979 | -- | 2.00 | -15.13 | -15.13 | 4.65 | 8.96 | 0.272 | 2.98 | 9.91 | 223,832.50 | -86.08 | -73.55 | -132.01 | -123.30 | 46.21 | -- | -316.50 | -476.22 | 2.26 | -241.14 | 0.0012 | -- | -1.90 | 74.49 | -4.06 | -- | -- | -- |
| Aspire Biopharma Holdings Inc | 1.94k | -28.70m | 7.29m | -- | -- | -- | -- | 3,755.16 | -65.96 | -65.96 | 0.0022 | -9.26 | 0.0004 | -- | -- | -- | -633.21 | -- | -- | -- | 45.36 | -- | -1,479,598.00 | -- | 0.1708 | -6.20 | -- | -- | -- | -- | -380.85 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -23.06m | 7.30m | 14.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0188 | 0.00 | -- | -- | 0.00 | -148.18 | -58.12 | -194.91 | -64.99 | -- | -- | -- | -- | -- | -- | 1.03 | -- | -- | -- | 60.12 | -- | -57.90 | -- |
| TRON Group Inc | 1.01m | -549.47k | 7.38m | 50.00 | -- | -- | -- | 7.31 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 7.41m | 1.00 | -- | 2.61 | -- | 1,234.95 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -8.54m | 7.58m | 12.00 | -- | 0.3156 | -- | -- | -2.05 | -2.05 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -24.99 | -48.77 | -27.44 | -56.18 | -- | -- | -- | -276.73 | -- | -- | 0.00 | -- | -- | 42.93 | 127.56 | -- | -- | -- |
| Synlogic Inc | 0.00 | -3.23m | 7.60m | 1.00 | -- | 0.7365 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Alzamend Neuro Inc | 0.00 | -6.47m | 7.65m | 4.00 | -- | 1.75 | -- | -- | -5.71 | -5.71 | 0.00 | 1.15 | 0.00 | -- | -- | 0.00 | -116.49 | -171.97 | -144.76 | -256.71 | -- | -- | -- | -- | -- | -766.93 | 0.00 | -- | -- | -- | 48.68 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to CalciMedica Inc's reporting currency: US Dollar USD
17.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 683.90k | 4.75% |
| Aisling Capital Management LPas of 31 Dec 2025 | 521.11k | 3.62% |
| Pengana Capital Ltd.as of 31 Oct 2025 | 449.00k | 3.12% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 356.13k | 2.47% |
| Geode Capital Management LLCas of 31 Dec 2025 | 99.79k | 0.69% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 88.30k | 0.61% |
| Boothbay Fund Management LLCas of 31 Dec 2025 | 76.86k | 0.53% |
| Envestnet Asset Management, Inc.as of 31 Dec 2025 | 63.19k | 0.44% |
| Meritage Portfolio Management, Inc.as of 31 Dec 2025 | 61.54k | 0.43% |
| Stonehage Fleming Investment Management Ltd.as of 31 Dec 2025 | 53.70k | 0.37% |
More ▼
Data from 31 Oct 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
